nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Pilocarpine—glaucoma	0.0803	0.236	CbGbCtD
Pimecrolimus—CYP3A4—Brinzolamide—glaucoma	0.063	0.185	CbGbCtD
Pimecrolimus—CYP3A4—Dorzolamide—glaucoma	0.0608	0.178	CbGbCtD
Pimecrolimus—CYP3A4—Methazolamide—glaucoma	0.0542	0.159	CbGbCtD
Pimecrolimus—CYP3A4—Acetazolamide—glaucoma	0.0433	0.127	CbGbCtD
Pimecrolimus—CYP3A4—Clonidine—glaucoma	0.0392	0.115	CbGbCtD
Pimecrolimus—MTOR—Signaling by PDGF—NCK2—glaucoma	0.000885	0.00414	CbGpPWpGaD
Pimecrolimus—CYP3A4—Estrogen metabolism—CYP1B1—glaucoma	0.00081	0.00379	CbGpPWpGaD
Pimecrolimus—MTOR—Type II diabetes mellitus—TNF—glaucoma	0.000792	0.00371	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—BAD—glaucoma	0.000778	0.00364	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—BCL2L1—glaucoma	0.000768	0.0036	CbGpPWpGaD
Pimecrolimus—MTOR—Class I PI3K signaling events mediated by Akt—CDKN1B—glaucoma	0.000766	0.00359	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000751	0.00352	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—MMP1—glaucoma	0.000744	0.00348	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—EDN1—glaucoma	0.000721	0.00337	CbGpPWpGaD
Pimecrolimus—CYP3A4—Tamoxifen metabolism—CYP1B1—glaucoma	0.000716	0.00335	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—LRP12—glaucoma	0.000711	0.00333	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—NTRK1—glaucoma	0.000703	0.00329	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000692	0.00324	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000688	0.00322	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—glaucoma	0.000686	0.00321	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—RPTOR—glaucoma	0.000679	0.00318	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—BCL2L1—glaucoma	0.00066	0.00309	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—NTRK2—glaucoma	0.00065	0.00304	CbGpPWpGaD
Pimecrolimus—CYP3A4—Estrogen metabolism—GSTM1—glaucoma	0.000648	0.00303	CbGpPWpGaD
Pimecrolimus—Headache—Diclofenamide—glaucoma	0.000647	0.00145	CcSEcCtD
Pimecrolimus—Cough—Dorzolamide—glaucoma	0.000645	0.00145	CcSEcCtD
Pimecrolimus—Rhinitis—Clonidine—glaucoma	0.000643	0.00144	CcSEcCtD
Pimecrolimus—Cough—Travoprost—glaucoma	0.000642	0.00144	CcSEcCtD
Pimecrolimus—Vomiting—Carbachol—glaucoma	0.000641	0.00144	CcSEcCtD
Pimecrolimus—Dyspnoea—Bimatoprost—glaucoma	0.000636	0.00143	CcSEcCtD
Pimecrolimus—Rash—Carbachol—glaucoma	0.000636	0.00143	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Apraclonidine—glaucoma	0.000635	0.00143	CcSEcCtD
Pimecrolimus—Dermatitis—Carbachol—glaucoma	0.000635	0.00143	CcSEcCtD
Pimecrolimus—Cough—Brinzolamide—glaucoma	0.000634	0.00142	CcSEcCtD
Pimecrolimus—Oedema—Brimonidine—glaucoma	0.000632	0.00142	CcSEcCtD
Pimecrolimus—Headache—Carbachol—glaucoma	0.000632	0.00142	CcSEcCtD
Pimecrolimus—Arthralgia—Dorzolamide—glaucoma	0.000629	0.00141	CcSEcCtD
Pimecrolimus—Pain—Apraclonidine—glaucoma	0.000629	0.00141	CcSEcCtD
Pimecrolimus—Constipation—Apraclonidine—glaucoma	0.000629	0.00141	CcSEcCtD
Pimecrolimus—Infection—Brimonidine—glaucoma	0.000628	0.00141	CcSEcCtD
Pimecrolimus—Arthralgia—Travoprost—glaucoma	0.000627	0.00141	CcSEcCtD
Pimecrolimus—Pneumonia—Betaxolol—glaucoma	0.000625	0.0014	CcSEcCtD
Pimecrolimus—Nausea—Carteolol—glaucoma	0.000624	0.0014	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.000622	0.0014	CcSEcCtD
Pimecrolimus—Headache—Levobunolol—glaucoma	0.000622	0.0014	CcSEcCtD
Pimecrolimus—Infestation NOS—Betaxolol—glaucoma	0.000622	0.00139	CcSEcCtD
Pimecrolimus—Infestation—Betaxolol—glaucoma	0.000622	0.00139	CcSEcCtD
Pimecrolimus—Nervous system disorder—Brimonidine—glaucoma	0.00062	0.00139	CcSEcCtD
Pimecrolimus—Arthralgia—Brinzolamide—glaucoma	0.000619	0.00139	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Bimatoprost—glaucoma	0.000616	0.00138	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.000615	0.00138	CcSEcCtD
Pimecrolimus—Skin disorder—Brimonidine—glaucoma	0.000614	0.00138	CcSEcCtD
Pimecrolimus—Nausea—Diclofenamide—glaucoma	0.000614	0.00138	CcSEcCtD
Pimecrolimus—Pain—Bimatoprost—glaucoma	0.00061	0.00137	CcSEcCtD
Pimecrolimus—Cough—Pilocarpine—glaucoma	0.00061	0.00137	CcSEcCtD
Pimecrolimus—Vomiting—Methazolamide—glaucoma	0.000605	0.00136	CcSEcCtD
Pimecrolimus—Conjunctivitis—Betaxolol—glaucoma	0.000604	0.00136	CcSEcCtD
Pimecrolimus—Oedema—Dorzolamide—glaucoma	0.000603	0.00135	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Dorzolamide—glaucoma	0.000603	0.00135	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Apraclonidine—glaucoma	0.000602	0.00135	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Timolol—glaucoma	0.000602	0.00135	CcSEcCtD
Pimecrolimus—Oedema—Travoprost—glaucoma	0.000601	0.00135	CcSEcCtD
Pimecrolimus—Rash—Methazolamide—glaucoma	0.0006	0.00135	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL1A—glaucoma	0.000599	0.00281	CbGpPWpGaD
Pimecrolimus—Dermatitis—Methazolamide—glaucoma	0.000599	0.00134	CcSEcCtD
Pimecrolimus—Eye disorder—Clonidine—glaucoma	0.000599	0.00134	CcSEcCtD
Pimecrolimus—Nausea—Carbachol—glaucoma	0.000599	0.00134	CcSEcCtD
Pimecrolimus—MTOR—Leptin signaling pathway—BAD—glaucoma	0.000598	0.0028	CbGpPWpGaD
Pimecrolimus—Infection—Travoprost—glaucoma	0.000597	0.00134	CcSEcCtD
Pimecrolimus—Headache—Methazolamide—glaucoma	0.000596	0.00134	CcSEcCtD
Pimecrolimus—Breast disorder—Timolol—glaucoma	0.000595	0.00134	CcSEcCtD
Pimecrolimus—Arthralgia—Pilocarpine—glaucoma	0.000595	0.00133	CcSEcCtD
Pimecrolimus—Paraesthesia—Acetazolamide—glaucoma	0.000591	0.00133	CcSEcCtD
Pimecrolimus—Nausea—Levobunolol—glaucoma	0.00059	0.00132	CcSEcCtD
Pimecrolimus—Infection—Brinzolamide—glaucoma	0.000589	0.00132	CcSEcCtD
Pimecrolimus—Nervous system disorder—Travoprost—glaucoma	0.000589	0.00132	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Timolol—glaucoma	0.000589	0.00132	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	0.000588	0.00276	CbGpPWpGaD
Pimecrolimus—Epistaxis—Betaxolol—glaucoma	0.000586	0.00132	CcSEcCtD
Pimecrolimus—Skin disorder—Travoprost—glaucoma	0.000584	0.00131	CcSEcCtD
Pimecrolimus—Sinusitis—Betaxolol—glaucoma	0.000583	0.00131	CcSEcCtD
Pimecrolimus—Abdominal pain—Apraclonidine—glaucoma	0.000582	0.00131	CcSEcCtD
Pimecrolimus—Nervous system disorder—Brinzolamide—glaucoma	0.000582	0.00131	CcSEcCtD
Pimecrolimus—Rash—Latanoprost—glaucoma	0.00058	0.0013	CcSEcCtD
Pimecrolimus—Dermatitis—Latanoprost—glaucoma	0.00058	0.0013	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Clonidine—glaucoma	0.000578	0.0013	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—TXN—glaucoma	0.000577	0.0027	CbGpPWpGaD
Pimecrolimus—Headache—Latanoprost—glaucoma	0.000577	0.00129	CcSEcCtD
Pimecrolimus—Skin disorder—Brinzolamide—glaucoma	0.000576	0.00129	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Brimonidine—glaucoma	0.000576	0.00129	CcSEcCtD
Pimecrolimus—MTOR—PI3K/AKT activation—NGF—glaucoma	0.000571	0.00268	CbGpPWpGaD
Pimecrolimus—Oedema—Pilocarpine—glaucoma	0.00057	0.00128	CcSEcCtD
Pimecrolimus—Asthma—Timolol—glaucoma	0.000569	0.00128	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000568	0.00128	CcSEcCtD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—BAD—glaucoma	0.000568	0.00266	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Brimonidine—glaucoma	0.000567	0.00127	CcSEcCtD
Pimecrolimus—Infection—Pilocarpine—glaucoma	0.000566	0.00127	CcSEcCtD
Pimecrolimus—Nausea—Methazolamide—glaucoma	0.000565	0.00127	CcSEcCtD
Pimecrolimus—Dyspnoea—Brimonidine—glaucoma	0.000563	0.00126	CcSEcCtD
Pimecrolimus—Rhinitis—Betaxolol—glaucoma	0.000559	0.00126	CcSEcCtD
Pimecrolimus—Erythema—Clonidine—glaucoma	0.000558	0.00125	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—NGFR—glaucoma	0.000557	0.00261	CbGpPWpGaD
Pimecrolimus—Pharyngitis—Betaxolol—glaucoma	0.000554	0.00124	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.00055	0.00123	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Travoprost—glaucoma	0.000547	0.00123	CcSEcCtD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—BAD—glaucoma	0.000546	0.00256	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Brimonidine—glaucoma	0.000546	0.00122	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—PTGS2—glaucoma	0.000544	0.00255	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Apraclonidine—glaucoma	0.000542	0.00122	CcSEcCtD
Pimecrolimus—Paraesthesia—Dorzolamide—glaucoma	0.000542	0.00122	CcSEcCtD
Pimecrolimus—MTOR—ErbB Signaling Pathway—CDKN1B—glaucoma	0.000542	0.00254	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.00054	0.00121	CcSEcCtD
Pimecrolimus—Pain—Brimonidine—glaucoma	0.00054	0.00121	CcSEcCtD
Pimecrolimus—Dyspnoea—Dorzolamide—glaucoma	0.000538	0.00121	CcSEcCtD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—BAD—glaucoma	0.000536	0.00251	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Travoprost—glaucoma	0.000536	0.0012	CcSEcCtD
Pimecrolimus—Paraesthesia—Brinzolamide—glaucoma	0.000533	0.0012	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—NTRK1—glaucoma	0.000529	0.00248	CbGpPWpGaD
Pimecrolimus—Upper respiratory tract infection—Timolol—glaucoma	0.000529	0.00119	CcSEcCtD
Pimecrolimus—Dyspnoea—Brinzolamide—glaucoma	0.000529	0.00119	CcSEcCtD
Pimecrolimus—Urticaria—Acetazolamide—glaucoma	0.000523	0.00117	CcSEcCtD
Pimecrolimus—Eye disorder—Betaxolol—glaucoma	0.000521	0.00117	CcSEcCtD
Pimecrolimus—Pruritus—Apraclonidine—glaucoma	0.000521	0.00117	CcSEcCtD
Pimecrolimus—Body temperature increased—Acetazolamide—glaucoma	0.00052	0.00117	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.000519	0.00117	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Travoprost—glaucoma	0.000519	0.00116	CcSEcCtD
Pimecrolimus—Flushing—Betaxolol—glaucoma	0.000518	0.00116	CcSEcCtD
Pimecrolimus—Pain—Dorzolamide—glaucoma	0.000516	0.00116	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—CDKN1B—glaucoma	0.000515	0.00241	CbGpPWpGaD
Pimecrolimus—Constipation—Travoprost—glaucoma	0.000514	0.00115	CcSEcCtD
Pimecrolimus—Pain—Travoprost—glaucoma	0.000514	0.00115	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000512	0.00115	CcSEcCtD
Pimecrolimus—Paraesthesia—Pilocarpine—glaucoma	0.000512	0.00115	CcSEcCtD
Pimecrolimus—Angioedema—Clonidine—glaucoma	0.00051	0.00114	CcSEcCtD
Pimecrolimus—Dyspnoea—Pilocarpine—glaucoma	0.000508	0.00114	CcSEcCtD
Pimecrolimus—Pain—Brinzolamide—glaucoma	0.000507	0.00114	CcSEcCtD
Pimecrolimus—Pruritus—Bimatoprost—glaucoma	0.000505	0.00113	CcSEcCtD
Pimecrolimus—MTOR—ErbB1 downstream signaling—BCL2L1—glaucoma	0.000504	0.00236	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Betaxolol—glaucoma	0.000504	0.00113	CcSEcCtD
Pimecrolimus—Diarrhoea—Apraclonidine—glaucoma	0.000504	0.00113	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	0.000503	0.00236	CbGpPWpGaD
Pimecrolimus—Mediastinal disorder—Betaxolol—glaucoma	0.000503	0.00113	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—LRP12—glaucoma	0.000498	0.00233	CbGpPWpGaD
Pimecrolimus—Conjunctivitis—Timolol—glaucoma	0.000494	0.00111	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dorzolamide—glaucoma	0.000493	0.00111	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000492	0.0011	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Travoprost—glaucoma	0.000491	0.0011	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NTRK2—glaucoma	0.000488	0.00228	CbGpPWpGaD
Pimecrolimus—Pain—Pilocarpine—glaucoma	0.000488	0.00109	CcSEcCtD
Pimecrolimus—Constipation—Pilocarpine—glaucoma	0.000488	0.00109	CcSEcCtD
Pimecrolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000487	0.00228	CbGpPWpGaD
Pimecrolimus—Cough—Clonidine—glaucoma	0.000487	0.00109	CcSEcCtD
Pimecrolimus—Malnutrition—Betaxolol—glaucoma	0.000486	0.00109	CcSEcCtD
Pimecrolimus—Erythema—Betaxolol—glaucoma	0.000486	0.00109	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—BDNF—glaucoma	0.000485	0.00227	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—BAD—glaucoma	0.000483	0.00226	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—NOS3—glaucoma	0.000481	0.00225	CbGpPWpGaD
Pimecrolimus—Urticaria—Dorzolamide—glaucoma	0.000479	0.00108	CcSEcCtD
Pimecrolimus—Epistaxis—Timolol—glaucoma	0.000479	0.00107	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—CAV1—glaucoma	0.000478	0.00224	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—MMP9—glaucoma	0.000477	0.00223	CbGpPWpGaD
Pimecrolimus—Abdominal pain—Dorzolamide—glaucoma	0.000477	0.00107	CcSEcCtD
Pimecrolimus—Body temperature increased—Dorzolamide—glaucoma	0.000477	0.00107	CcSEcCtD
Pimecrolimus—Sinusitis—Timolol—glaucoma	0.000476	0.00107	CcSEcCtD
Pimecrolimus—Arthralgia—Clonidine—glaucoma	0.000475	0.00107	CcSEcCtD
Pimecrolimus—Abdominal pain—Travoprost—glaucoma	0.000475	0.00107	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000472	0.00106	CcSEcCtD
Pimecrolimus—Urticaria—Brinzolamide—glaucoma	0.000471	0.00106	CcSEcCtD
Pimecrolimus—MTOR—PI3K/AKT activation—BAD—glaucoma	0.000471	0.00221	CbGpPWpGaD
Pimecrolimus—Vomiting—Apraclonidine—glaucoma	0.000468	0.00105	CcSEcCtD
Pimecrolimus—MTOR—GAB1 signalosome—BAD—glaucoma	0.000468	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—CDKN1B—glaucoma	0.000467	0.00219	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Pilocarpine—glaucoma	0.000466	0.00105	CcSEcCtD
Pimecrolimus—Hypersensitivity—Brimonidine—glaucoma	0.000466	0.00104	CcSEcCtD
Pimecrolimus—Dermatitis—Apraclonidine—glaucoma	0.000464	0.00104	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—FN1—glaucoma	0.000462	0.00216	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—CDKN1B—glaucoma	0.000461	0.00216	CbGpPWpGaD
Pimecrolimus—Headache—Apraclonidine—glaucoma	0.000461	0.00103	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—FGFR1OP—glaucoma	0.000458	0.00214	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HEYL—glaucoma	0.000458	0.00214	CbGpPWpGaD
Pimecrolimus—Rhinitis—Timolol—glaucoma	0.000457	0.00103	CcSEcCtD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—BAD—glaucoma	0.000457	0.00214	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—BAD—glaucoma	0.000457	0.00214	CbGpPWpGaD
Pimecrolimus—Oedema—Clonidine—glaucoma	0.000455	0.00102	CcSEcCtD
Pimecrolimus—Infection—Clonidine—glaucoma	0.000452	0.00102	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—CAV1—glaucoma	0.000452	0.00211	CbGpPWpGaD
Pimecrolimus—Abdominal pain—Pilocarpine—glaucoma	0.000451	0.00101	CcSEcCtD
Pimecrolimus—Body temperature increased—Pilocarpine—glaucoma	0.000451	0.00101	CcSEcCtD
Pimecrolimus—Diarrhoea—Acetazolamide—glaucoma	0.00045	0.00101	CcSEcCtD
Pimecrolimus—MTOR—Regulation of Telomerase—CDKN1B—glaucoma	0.00045	0.00211	CbGpPWpGaD
Pimecrolimus—Rash—Bimatoprost—glaucoma	0.00045	0.00101	CcSEcCtD
Pimecrolimus—Dermatitis—Bimatoprost—glaucoma	0.00045	0.00101	CcSEcCtD
Pimecrolimus—Pruritus—Brimonidine—glaucoma	0.000447	0.001	CcSEcCtD
Pimecrolimus—Headache—Bimatoprost—glaucoma	0.000447	0.001	CcSEcCtD
Pimecrolimus—Nervous system disorder—Clonidine—glaucoma	0.000447	0.001	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CTSA—glaucoma	0.000446	0.00209	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Dorzolamide—glaucoma	0.000445	0.000998	CcSEcCtD
Pimecrolimus—Hypersensitivity—Travoprost—glaucoma	0.000443	0.000993	CcSEcCtD
Pimecrolimus—Skin disorder—Clonidine—glaucoma	0.000442	0.000993	CcSEcCtD
Pimecrolimus—Nausea—Apraclonidine—glaucoma	0.000437	0.000981	CcSEcCtD
Pimecrolimus—Hypersensitivity—Brinzolamide—glaucoma	0.000437	0.000981	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—NGF—glaucoma	0.00043	0.00201	CbGpPWpGaD
Pimecrolimus—Pruritus—Dorzolamide—glaucoma	0.000427	0.000958	CcSEcCtD
Pimecrolimus—Eye disorder—Timolol—glaucoma	0.000426	0.000956	CcSEcCtD
Pimecrolimus—Pruritus—Travoprost—glaucoma	0.000425	0.000954	CcSEcCtD
Pimecrolimus—Cough—Betaxolol—glaucoma	0.000424	0.000951	CcSEcCtD
Pimecrolimus—Nausea—Bimatoprost—glaucoma	0.000424	0.000951	CcSEcCtD
Pimecrolimus—Hypersensitivity—Pilocarpine—glaucoma	0.00042	0.000943	CcSEcCtD
Pimecrolimus—Pruritus—Brinzolamide—glaucoma	0.00042	0.000942	CcSEcCtD
Pimecrolimus—Vomiting—Acetazolamide—glaucoma	0.000419	0.000939	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Clonidine—glaucoma	0.000415	0.000931	CcSEcCtD
Pimecrolimus—Arthralgia—Betaxolol—glaucoma	0.000414	0.000928	CcSEcCtD
Pimecrolimus—Diarrhoea—Dorzolamide—glaucoma	0.000413	0.000927	CcSEcCtD
Pimecrolimus—Headache—Acetazolamide—glaucoma	0.000412	0.000926	CcSEcCtD
Pimecrolimus—Immune system disorder—Timolol—glaucoma	0.000412	0.000924	CcSEcCtD
Pimecrolimus—Diarrhoea—Travoprost—glaucoma	0.000411	0.000923	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Timolol—glaucoma	0.000411	0.000922	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000411	0.000922	CcSEcCtD
Pimecrolimus—Paraesthesia—Clonidine—glaucoma	0.000409	0.000918	CcSEcCtD
Pimecrolimus—MTOR—LKB1 signaling events—TP53—glaucoma	0.000408	0.00191	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Clonidine—glaucoma	0.000406	0.000911	CcSEcCtD
Pimecrolimus—Diarrhoea—Brinzolamide—glaucoma	0.000406	0.000911	CcSEcCtD
Pimecrolimus—Pruritus—Pilocarpine—glaucoma	0.000403	0.000905	CcSEcCtD
Pimecrolimus—MTOR—Disease—LRP12—glaucoma	0.0004	0.00187	CbGpPWpGaD
Pimecrolimus—Rash—Brimonidine—glaucoma	0.000398	0.000894	CcSEcCtD
Pimecrolimus—Dermatitis—Brimonidine—glaucoma	0.000398	0.000893	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NTRK1—glaucoma	0.000398	0.00186	CbGpPWpGaD
Pimecrolimus—Malnutrition—Timolol—glaucoma	0.000397	0.00089	CcSEcCtD
Pimecrolimus—Erythema—Timolol—glaucoma	0.000397	0.00089	CcSEcCtD
Pimecrolimus—Oedema—Betaxolol—glaucoma	0.000396	0.00089	CcSEcCtD
Pimecrolimus—Headache—Brimonidine—glaucoma	0.000396	0.000888	CcSEcCtD
Pimecrolimus—Infection—Betaxolol—glaucoma	0.000394	0.000884	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Clonidine—glaucoma	0.000393	0.000882	CcSEcCtD
Pimecrolimus—Nausea—Acetazolamide—glaucoma	0.000391	0.000878	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—TXNIP—glaucoma	0.000391	0.00183	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Pilocarpine—glaucoma	0.00039	0.000875	CcSEcCtD
Pimecrolimus—Constipation—Clonidine—glaucoma	0.000389	0.000874	CcSEcCtD
Pimecrolimus—Pain—Clonidine—glaucoma	0.000389	0.000874	CcSEcCtD
Pimecrolimus—Nervous system disorder—Betaxolol—glaucoma	0.000389	0.000872	CcSEcCtD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—glaucoma	0.000388	0.00182	CbGpPWpGaD
Pimecrolimus—Skin disorder—Betaxolol—glaucoma	0.000385	0.000864	CcSEcCtD
Pimecrolimus—Vomiting—Dorzolamide—glaucoma	0.000384	0.000861	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—TBK1—glaucoma	0.000383	0.00179	CbGpPWpGaD
Pimecrolimus—CYP3A4—Tryptophan metabolism—CYP1B1—glaucoma	0.000383	0.00179	CbGpPWpGaD
Pimecrolimus—Rash—Dorzolamide—glaucoma	0.00038	0.000854	CcSEcCtD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—TNF—glaucoma	0.00038	0.00178	CbGpPWpGaD
Pimecrolimus—Dermatitis—Dorzolamide—glaucoma	0.00038	0.000853	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MMP1—glaucoma	0.000379	0.00177	CbGpPWpGaD
Pimecrolimus—Rash—Travoprost—glaucoma	0.000379	0.00085	CcSEcCtD
Pimecrolimus—Dermatitis—Travoprost—glaucoma	0.000378	0.000849	CcSEcCtD
Pimecrolimus—Headache—Dorzolamide—glaucoma	0.000378	0.000848	CcSEcCtD
Pimecrolimus—Vomiting—Brinzolamide—glaucoma	0.000377	0.000846	CcSEcCtD
Pimecrolimus—Headache—Travoprost—glaucoma	0.000376	0.000845	CcSEcCtD
Pimecrolimus—Nausea—Brimonidine—glaucoma	0.000375	0.000842	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—NTRK2—glaucoma	0.000375	0.00176	CbGpPWpGaD
Pimecrolimus—Rash—Brinzolamide—glaucoma	0.000374	0.000839	CcSEcCtD
Pimecrolimus—Dermatitis—Brinzolamide—glaucoma	0.000374	0.000839	CcSEcCtD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—CDKN1B—glaucoma	0.000373	0.00175	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Clonidine—glaucoma	0.000372	0.000836	CcSEcCtD
Pimecrolimus—Headache—Brinzolamide—glaucoma	0.000372	0.000834	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	0.00037	0.00173	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TNF—glaucoma	0.000367	0.00172	CbGpPWpGaD
Pimecrolimus—Angioedema—Timolol—glaucoma	0.000363	0.000814	CcSEcCtD
Pimecrolimus—Vomiting—Pilocarpine—glaucoma	0.000363	0.000814	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—NOS3—glaucoma	0.000362	0.00169	CbGpPWpGaD
Pimecrolimus—Urticaria—Clonidine—glaucoma	0.000362	0.000812	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000361	0.00081	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—BAD—glaucoma	0.000361	0.00169	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Clonidine—glaucoma	0.00036	0.000808	CcSEcCtD
Pimecrolimus—Abdominal pain—Clonidine—glaucoma	0.00036	0.000808	CcSEcCtD
Pimecrolimus—Rash—Pilocarpine—glaucoma	0.00036	0.000807	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—glaucoma	0.000359	0.00168	CbGpPWpGaD
Pimecrolimus—Dermatitis—Pilocarpine—glaucoma	0.000359	0.000806	CcSEcCtD
Pimecrolimus—Nausea—Dorzolamide—glaucoma	0.000358	0.000804	CcSEcCtD
Pimecrolimus—Headache—Pilocarpine—glaucoma	0.000357	0.000802	CcSEcCtD
Pimecrolimus—Nausea—Travoprost—glaucoma	0.000357	0.000801	CcSEcCtD
Pimecrolimus—Paraesthesia—Betaxolol—glaucoma	0.000356	0.000799	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—BAD—glaucoma	0.000355	0.00166	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Betaxolol—glaucoma	0.000353	0.000793	CcSEcCtD
Pimecrolimus—Nausea—Brinzolamide—glaucoma	0.000352	0.000791	CcSEcCtD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—MMP9—glaucoma	0.000352	0.00165	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	0.000351	0.00164	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—C1QB—glaucoma	0.000346	0.00162	CbGpPWpGaD
Pimecrolimus—Cough—Timolol—glaucoma	0.000346	0.000777	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—BAD—glaucoma	0.000345	0.00162	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—OPN4—glaucoma	0.000345	0.00162	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—CAV1—glaucoma	0.000343	0.00161	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Betaxolol—glaucoma	0.000342	0.000768	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—BAD—glaucoma	0.000342	0.0016	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—NOS3—glaucoma	0.000342	0.0016	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—TP53—glaucoma	0.00034	0.00159	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—BAD—glaucoma	0.00034	0.00159	CbGpPWpGaD
Pimecrolimus—Constipation—Betaxolol—glaucoma	0.000339	0.000761	CcSEcCtD
Pimecrolimus—Pain—Betaxolol—glaucoma	0.000339	0.000761	CcSEcCtD
Pimecrolimus—Nausea—Pilocarpine—glaucoma	0.000339	0.00076	CcSEcCtD
Pimecrolimus—Arthralgia—Timolol—glaucoma	0.000338	0.000758	CcSEcCtD
Pimecrolimus—MTOR—PI-3K cascade—CDKN1B—glaucoma	0.000336	0.00157	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000336	0.000753	CcSEcCtD
Pimecrolimus—Hypersensitivity—Clonidine—glaucoma	0.000335	0.000753	CcSEcCtD
Pimecrolimus—MTOR—PI3K/AKT activation—CDKN1B—glaucoma	0.000328	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—CDKN1B—glaucoma	0.000326	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—BAD—glaucoma	0.000325	0.00152	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Timolol—glaucoma	0.000324	0.000727	CcSEcCtD
Pimecrolimus—Oedema—Timolol—glaucoma	0.000324	0.000727	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TP53—glaucoma	0.000324	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NGF—glaucoma	0.000323	0.00151	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—BAD—glaucoma	0.000323	0.00151	CbGpPWpGaD
Pimecrolimus—Pruritus—Clonidine—glaucoma	0.000322	0.000723	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—NGFR—glaucoma	0.000322	0.00151	CbGpPWpGaD
Pimecrolimus—Infection—Timolol—glaucoma	0.000322	0.000722	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—BAD—glaucoma	0.000321	0.0015	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HEYL—glaucoma	0.000321	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—BAD—glaucoma	0.00032	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—CDKN1B—glaucoma	0.000318	0.00149	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—CDKN1B—glaucoma	0.000318	0.00149	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—SOD1—glaucoma	0.000318	0.00149	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Timolol—glaucoma	0.000318	0.000713	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—BAD—glaucoma	0.000315	0.00148	CbGpPWpGaD
Pimecrolimus—Urticaria—Betaxolol—glaucoma	0.000315	0.000707	CcSEcCtD
Pimecrolimus—Skin disorder—Timolol—glaucoma	0.000315	0.000706	CcSEcCtD
Pimecrolimus—Body temperature increased—Betaxolol—glaucoma	0.000313	0.000703	CcSEcCtD
Pimecrolimus—Diarrhoea—Clonidine—glaucoma	0.000312	0.000699	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—PTGFR—glaucoma	0.000311	0.00145	CbGpPWpGaD
Pimecrolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000309	0.00145	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TXN—glaucoma	0.000309	0.00145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NTRK1—glaucoma	0.000306	0.00143	CbGpPWpGaD
Pimecrolimus—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000305	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—BAD—glaucoma	0.000301	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—BAD—glaucoma	0.000301	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—BAD—glaucoma	0.000301	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN2B—glaucoma	0.0003	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—BAD—glaucoma	0.000298	0.0014	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—BAD—glaucoma	0.000296	0.00138	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Timolol—glaucoma	0.000295	0.000662	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—BAD—glaucoma	0.000294	0.00138	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—glaucoma	0.000293	0.00137	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Betaxolol—glaucoma	0.000292	0.000655	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	0.000292	0.00136	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Timolol—glaucoma	0.000291	0.000653	CcSEcCtD
Pimecrolimus—Vomiting—Clonidine—glaucoma	0.00029	0.00065	CcSEcCtD
Pimecrolimus—Dyspnoea—Timolol—glaucoma	0.000289	0.000648	CcSEcCtD
Pimecrolimus—Rash—Clonidine—glaucoma	0.000287	0.000644	CcSEcCtD
Pimecrolimus—Dermatitis—Clonidine—glaucoma	0.000287	0.000644	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—IL1A—glaucoma	0.000287	0.00134	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HDAC9—glaucoma	0.000286	0.00134	CbGpPWpGaD
Pimecrolimus—Headache—Clonidine—glaucoma	0.000285	0.00064	CcSEcCtD
Pimecrolimus—Pruritus—Betaxolol—glaucoma	0.00028	0.000629	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—LRP12—glaucoma	0.00028	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—TP53—glaucoma	0.00028	0.00131	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Timolol—glaucoma	0.00028	0.000627	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—BAD—glaucoma	0.000278	0.0013	CbGpPWpGaD
Pimecrolimus—Pain—Timolol—glaucoma	0.000277	0.000621	CcSEcCtD
Pimecrolimus—Diarrhoea—Betaxolol—glaucoma	0.000271	0.000609	CcSEcCtD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—glaucoma	0.000271	0.00127	CbGpPWpGaD
Pimecrolimus—Nausea—Clonidine—glaucoma	0.00027	0.000607	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CTSA—glaucoma	0.00027	0.00127	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BAD—glaucoma	0.000266	0.00125	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Timolol—glaucoma	0.000265	0.000594	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—glaucoma	0.000261	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—NOS3—glaucoma	0.00026	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGFR1OP—glaucoma	0.000258	0.00121	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HEYL—glaucoma	0.000258	0.00121	CbGpPWpGaD
Pimecrolimus—Urticaria—Timolol—glaucoma	0.000257	0.000577	CcSEcCtD
Pimecrolimus—Abdominal pain—Timolol—glaucoma	0.000256	0.000575	CcSEcCtD
Pimecrolimus—Body temperature increased—Timolol—glaucoma	0.000256	0.000575	CcSEcCtD
Pimecrolimus—Vomiting—Betaxolol—glaucoma	0.000252	0.000566	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—CDKN1B—glaucoma	0.000251	0.00118	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000251	0.00117	CbGpPWpGaD
Pimecrolimus—Rash—Betaxolol—glaucoma	0.00025	0.000561	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	0.00025	0.00117	CbGpPWpGaD
Pimecrolimus—Dermatitis—Betaxolol—glaucoma	0.00025	0.00056	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—NGF—glaucoma	0.000249	0.00116	CbGpPWpGaD
Pimecrolimus—Headache—Betaxolol—glaucoma	0.000248	0.000557	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—VEGFA—glaucoma	0.000246	0.00115	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RPTOR—glaucoma	0.000243	0.00114	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—CDKN1B—glaucoma	0.00024	0.00113	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Timolol—glaucoma	0.000239	0.000535	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—CDKN1B—glaucoma	0.000237	0.00111	CbGpPWpGaD
Pimecrolimus—Nausea—Betaxolol—glaucoma	0.000235	0.000528	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—NCK2—glaucoma	0.000235	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—MMP9—glaucoma	0.000233	0.00109	CbGpPWpGaD
Pimecrolimus—Pruritus—Timolol—glaucoma	0.000229	0.000514	CcSEcCtD
Pimecrolimus—MTOR—Immune System—TXNIP—glaucoma	0.000227	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—CDKN1B—glaucoma	0.000226	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—CDKN1B—glaucoma	0.000225	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—CDKN1B—glaucoma	0.000224	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TBK1—glaucoma	0.000223	0.00104	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—CDKN1B—glaucoma	0.000223	0.00104	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Timolol—glaucoma	0.000222	0.000497	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	0.00022	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CDKN1B—glaucoma	0.000219	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—CDKN1B—glaucoma	0.00021	0.000981	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—CDKN1B—glaucoma	0.00021	0.000981	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CDKN1B—glaucoma	0.00021	0.000981	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—CDKN1B—glaucoma	0.000208	0.000972	CbGpPWpGaD
Pimecrolimus—Vomiting—Timolol—glaucoma	0.000206	0.000462	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—CDKN1B—glaucoma	0.000206	0.000964	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—BAD—glaucoma	0.000205	0.00096	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—CDKN1B—glaucoma	0.000205	0.000959	CbGpPWpGaD
Pimecrolimus—Rash—Timolol—glaucoma	0.000204	0.000458	CcSEcCtD
Pimecrolimus—Dermatitis—Timolol—glaucoma	0.000204	0.000458	CcSEcCtD
Pimecrolimus—Headache—Timolol—glaucoma	0.000203	0.000455	CcSEcCtD
Pimecrolimus—MTOR—Immune System—C1QB—glaucoma	0.000202	0.000944	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HDAC9—glaucoma	0.0002	0.000937	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—glaucoma	0.0002	0.000936	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—glaucoma	0.000198	0.000926	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—OPN4—glaucoma	0.000194	0.000908	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—CDKN1B—glaucoma	0.000194	0.000908	CbGpPWpGaD
Pimecrolimus—Nausea—Timolol—glaucoma	0.000192	0.000432	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1B—glaucoma	0.000186	0.000869	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HEYL—glaucoma	0.00018	0.000845	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TXN—glaucoma	0.00018	0.000842	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTGFR—glaucoma	0.000175	0.000818	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN2A—glaucoma	0.000172	0.000804	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—GSTT1—glaucoma	0.000167	0.000783	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HDAC9—glaucoma	0.000161	0.000753	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SMO—glaucoma	0.000157	0.000733	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN2B—glaucoma	0.000154	0.00072	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN1B—glaucoma	0.000152	0.000712	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—glaucoma	0.00015	0.0007	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NTRK2—glaucoma	0.000143	0.000671	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—CDKN1B—glaucoma	0.000143	0.000668	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RPTOR—glaucoma	0.000137	0.00064	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—C3—glaucoma	0.000135	0.000631	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP1B1—glaucoma	0.000133	0.000624	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NCK2—glaucoma	0.000132	0.00062	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	0.000131	0.000615	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—C3—glaucoma	0.000129	0.000606	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—BCL2L1—glaucoma	0.000129	0.000604	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTHFR—glaucoma	0.000129	0.000603	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—glaucoma	0.000127	0.000593	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NGFR—glaucoma	0.000123	0.000575	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—APOE—glaucoma	0.00012	0.000562	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CAV1—glaucoma	0.000119	0.000556	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NARFL—glaucoma	0.000117	0.000549	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CA5A—glaucoma	0.000117	0.000549	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—BAD—glaucoma	0.000117	0.000547	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NTRK1—glaucoma	0.000117	0.000547	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HDAC9—glaucoma	0.000113	0.000527	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—BAD—glaucoma	0.000112	0.000526	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—BAD—glaucoma	0.000112	0.000523	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN2B—glaucoma	0.000108	0.000504	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—GSTM1—glaucoma	0.000106	0.000499	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	0.000105	0.000492	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EDN1—glaucoma	0.000103	0.000484	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—glaucoma	9.56e-05	0.000448	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NGF—glaucoma	9.49e-05	0.000444	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—C3—glaucoma	9.02e-05	0.000422	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS3—glaucoma	8.99e-05	0.000421	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1A—glaucoma	8.93e-05	0.000418	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMO—glaucoma	8.81e-05	0.000412	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN2B—glaucoma	8.64e-05	0.000405	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOE—glaucoma	8.4e-05	0.000393	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CAV1—glaucoma	8.32e-05	0.00039	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—glaucoma	8.22e-05	0.000385	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CDKN1B—glaucoma	8.14e-05	0.000381	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NTRK2—glaucoma	8.06e-05	0.000377	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FN1—glaucoma	7.92e-05	0.000371	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—C3—glaucoma	7.85e-05	0.000367	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—BAD—glaucoma	7.83e-05	0.000366	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDKN1B—glaucoma	7.82e-05	0.000366	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN1B—glaucoma	7.78e-05	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2L1—glaucoma	7.51e-05	0.000352	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—glaucoma	7.25e-05	0.000339	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NGFR—glaucoma	6.91e-05	0.000324	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BAD—glaucoma	6.81e-05	0.000319	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOE—glaucoma	6.75e-05	0.000316	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CAV1—glaucoma	6.68e-05	0.000313	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NTRK1—glaucoma	6.57e-05	0.000308	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOS3—glaucoma	6.29e-05	0.000295	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—BAD—glaucoma	6.29e-05	0.000294	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN2B—glaucoma	6.05e-05	0.000283	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EDN1—glaucoma	5.81e-05	0.000272	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CA1—glaucoma	5.72e-05	0.000268	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CTSA—glaucoma	5.54e-05	0.000259	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1B—glaucoma	5.45e-05	0.000255	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NGF—glaucoma	5.34e-05	0.00025	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CA2—glaucoma	5.23e-05	0.000245	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—C3—glaucoma	5.07e-05	0.000238	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS3—glaucoma	5.05e-05	0.000237	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—glaucoma	5.05e-05	0.000236	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1B—glaucoma	4.74e-05	0.000222	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOE—glaucoma	4.72e-05	0.000221	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CAV1—glaucoma	4.68e-05	0.000219	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—glaucoma	4.62e-05	0.000216	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—glaucoma	4.53e-05	0.000212	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FN1—glaucoma	4.45e-05	0.000209	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BAD—glaucoma	4.4e-05	0.000206	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1B—glaucoma	4.38e-05	0.000205	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TXN—glaucoma	3.69e-05	0.000173	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOS3—glaucoma	3.54e-05	0.000166	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—glaucoma	3.43e-05	0.00016	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1B—glaucoma	3.07e-05	0.000144	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTT1—glaucoma	2.86e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—glaucoma	2.84e-05	0.000133	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—glaucoma	2.55e-05	0.000119	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCA1—glaucoma	2.28e-05	0.000107	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1B1—glaucoma	2.28e-05	0.000107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—glaucoma	1.93e-05	9.02e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTM1—glaucoma	1.82e-05	8.53e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—glaucoma	1.61e-05	7.54e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOE—glaucoma	1.5e-05	7.02e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAV1—glaucoma	1.48e-05	6.95e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NOS3—glaucoma	1.12e-05	5.26e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—glaucoma	1.03e-05	4.81e-05	CbGpPWpGaD
